Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Harvey

MOHS-Micrographic Surgery Newnan, GA Medical Doctor

NPI 1578526232 CMS profile 297802

1615 Highway 34 E Ste B, Newnan, GA 30265

Open in the dashboard

General payments

$16,999

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Harvey of Newnan, GA is reported in the CMS Open Payments database as having received $16,999 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,006 38
2024 General $786 28
2023 General $1,351 29
2022 General $355 11
2021 General $820 22
2020 General $244 15
2019 General $7,437 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Harvey
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to David Harvey were reported at $6,006. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year David Harvey MOHS-Micrographic Surgery median Middle half National median
2019 $7,437 $316 $106–$785 $163
2020 $244 $162 $68–$412 $114
2021 $820 $243 $87–$654 $132
2022 $355 $300 $102–$887 $149
2023 $1,351 $364 $125–$1,010 $160
2024 $786 $445 $142–$1,108 $164
2025 $6,006 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Misonix Inc $6,750 8 payments
  2. Regeneron Healthcare Solutions, Inc. $5,411 10 payments
  3. Merz North America, Inc. $1,100 5 payments
  4. Genzyme Corporation $708 18 payments
  5. AbbVie, Inc. $308 13 payments
  6. Amgen Inc. $245 9 payments
  7. Arcutis Biotherapeutics, Inc. $226 15 payments
  8. Biofrontera Inc. $214 5 payments
  9. Sun Pharmaceutical Industries Inc. $203 11 payments
  10. Lilly USA, LLC $202 8 payments
  11. Other $1,631 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,632 3 payments
  2. Consulting Fee $5,162 2 payments
  3. Food and Beverage $5,020 170 payments
  4. Education $101 3 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83 1 payment
Products named General payments · program years 2019–2025
  1. TheraSkin $6,750 8 payments
  2. LIBTAYO $5,353 10 payments
  3. Xeomin $796 3 payments
  4. DUPIXENT $584 13 payments
  5. Otezla $245 9 payments
  6. RINVOQ $215 9 payments
  7. XEPI $193 4 payments
  8. Ameluz $169 3 payments
  9. BF-RhodoLED $169 3 payments
  10. TALTZ $168 7 payments
  11. Other $3,618 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

958

Median for Dermatology: 534

Drug cost

$86,428

Median for Dermatology: $67,151

Branded share of claims

13%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 16 $77,658
Mupirocin Generic 441 $3,329
Doxycycline Hyclate Generic 111 $1,004
Gentamicin Sulfate Generic 31 $955
Cefadroxil Generic 66 $586
Clobetasol Propionate Generic 25 $546
Erythromycin Erythromycin Base Brand 30 $383
Valacyclovir Valacyclovir Hcl Brand 15 $379
Triamcinolone Acetonide Generic 24 $346
Ketoconazole Generic 34 $320

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$310,450

Of which drugs: $765

Medicare patients

639

Average age 76

Services billed

3,368

288 women, 351 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 31%
Ischemic heart disease 30%
Diabetes 27%
Atrial fibrillation 19%
Depression 16%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fluorouracil, 500 mg J9190 Office 33 54 $124
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 26 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $247
$247 16 —
Otezla
  • Amgen Inc. $102
$102 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $84
$84 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $29
$29 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record